To address the growing use of ad blockers we now use affiliate links to sites like Amazon.com, streaming services, and others. Affiliate links help sites like QualityCounts.com stay open. Affiliate links cost you nothing but help me support my family. We do not allow paid reviews on this site. As an Amazon Associate I earn from qualifying purchases.  Also, you can donate  to ben@qualitycounts.com via Zelle or PayPal.  Click here for the PayPal QR.  Click here for Bitcoin QR code or Bitcoin address: 39muDw6WpQV8j6EdA8eUBvT5iFDiVpVpiE
Home ReliableRXPharmacy Past Newsletters Amazon.com Contact
 Sign-up for newsletter 
 Newsletter Archive
 Newsletter via RSS Feed
 Research on Supplements
 Health Conditions
 Anti-aging Recommendations
 Insulin and Aging
 QualityCounts.com in Time
 Longevity Affiliates:

Home > Health Conditions > Diabetes > Diabeta (glyburide)

Diabeta, Micronase (glyburide/glibenclamide)

Related Topics:

News & Research:

  • Glyburide - rxlsit.com - "Glyburide appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets"
  • Common Diabetes Drugs May Carry Risk, Study Suggests - WebMD, 9/26/13 - "Both metformin (brand names include Glucophage and Fortamet) and sulfonylureas (glyburide and glipizide) are commonly prescribed as first-line therapies for patients and have been available since the 1950s ... Patients who took sulfonylureas only were 58 percent more likely to die from any cause than those who took metformin only ... Sulfonylureas work "by increasing insulin release from the beta cells in the pancreas," while metformin "acts by suppressing glucose production by the liver,""
  • Common diabetes drugs associated with increased risk of death - Science Daily, 6/25/12 - "The drugs, glipizide, glyburide, and glimepiride ... We have clearly demonstrated that metformin is associated with a substantial reduction in mortality risk, and, thus, should be the preferred first-line agent, if one has a choice between metformin and a sulfonylurea ... Investigators found that all three sulfonylureas studied were associated with a more than 50 percent greater risk of death compared to metformin"
  • Glyburide a Risk for Diabetes Patients With Emergent PCI?: Glyburide Increases Risk in Patients With Diabetes Mellitus After Emergent Percutaneous Intervention for Myocardial Infarction – A Nationwide Study - Medscape, 11/28/11 - "The adjusted Cox models showed an increased risk for cardiovascular mortality with glyburide (hazard ratio [HR], 2.91; 95% confidence interval [CI] 1.26-6.72; P = .012) compared with metformin. The risk for cardiovascular mortality and nonfatal MI (HR, 2.69; CI, 1.21-6.00; P = .016) and the risk for all-cause mortality (HR, 2.46; CI, 1.11-5.47; P = .027) were also increased in patients receiving glyburide"
  • PERISCOPE Analysis Highlights TZD Lipid Effects - Medscape, 1/10/11 - "In that randomized comparison of the thiazolidinedione (TZD) vs glimepiride(Amaryl, Sanofi-Aventis) in patients with diabetes [2], those taking the TZD saw significantly less coronary disease progression as assessed with intravascular ultrasound (IVUS) over 18 months compared with those taking the other drug, a sulfonylurea. They also benefited with steeper declines in fasting insulin and blood glucose levels, glycated hemoglobin (HbA1C), C-reactive protein (CRP), and triglycerides as well as improved HDL-cholesterol levels ... the post hoc analysis "ties nicely" with the 2006 CHICAGOstudy, in which elevations in HDL were the most important predictor of reduced progression of carotid intima-media thickness"
  • Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes - Atherosclerosis. 2008 Dec 6 - "In patients with type 2 diabetes already on metformin, addition of pioglitazone as compared to glimepiride, improved endothelial function despite similar glycemic control. The improvement in endothelial function was mainly due to a reduction in insulin resistance"
  • Diabetes Drugs Compared - WebMD, 12/6/06 - "Avandia had the lowest treatment failure rate -- 15% -- compared with 21% for Glucophage and 34% for Micronase"
  • Long-term Safety of Pioglitazone vs Glyburide for Type 2 Diabetes - Medscape, 12/1/06 - "Patients with type 2 diabetes mellitus achieve glycemic control safely and effectively with both pioglitazone and glyburide treatment; however, the results of this study suggest that long-term treatment with pioglitazone is superior to glyburide with respect to tolerability. Overall, pioglitazone treatment resulted in sustained glycemic control, fewer patient withdrawals due to lack of efficacy or hypoglycemia, and fewer cardiac events compared with glyburide"
  • Metformin-Glibenclamide Combination Is More Effective Than Monotherapy In Type 2 Diabetes - Doctor's Guide, 4/24/03
  • Glyburide/Metformin Combination Effective For Type 2 Diabetes Inadequately Controlled By Sulphonylurea - Doctor's Guide, 2/3/02


  • Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy - N Engl J Med. 2006 Dec 4- "Kaplan-Meier analysis showed a cumulative incidence of monotherapy failure at 5 years of 15% with rosiglitazone, 21% with metformin, and 34% with glyburide. This represents a risk reduction of 32% for rosiglitazone, as compared with metformin, and 63%, as compared with glyburide (P<0.001 for both comparisons). The difference in the durability of the treatment effect was greater between rosiglitazone and glyburide than between rosiglitazone and metformin. Glyburide was associated with a lower risk of cardiovascular events (including congestive heart failure) than was rosiglitazone (P<0.05), and the risk associated with metformin was similar to that with rosiglitazone. Rosiglitazone was associated with more weight gain and edema than either metformin or glyburide but with fewer gastrointestinal events than metformin and with less hypoglycemia than glyburide"
  • Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome - Endocrine 2003 Apr;20(3):215-8 - "CRP level was significantly lower in patients using metformin for blood glucose control compared with those using glibenclamide, 5.56 and 8.3 mg/L, respectively ... The data showed that metformin decreases the level of circulating CRP, a marker of inflammation, more than glibenclamide"

Related Sites: